Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study

BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is linked to high mortality, primarily through an intense inflammatory response. Diacerein has emerged as a potential therapy for COVID-19 due to its potential impact in decreasing the inflammasome activation and coronavirus repl...

Description complète

Détails bibliographiques

Auteurs principaux:	Helison R. P. Carmo, Alejandro Rossel Castillo, Isabella Bonilha, Erica I. L. Gomes, Joaquim Barreto, Filipe A. Moura, Gustavo Gastão Davanzo, Lauar de Brito Monteiro, Stéfanie Primon Muraro, Gabriela Fabiano de Souza, Joseane Morari, Flávia Elisa Galdino, Natália S. Brunetti, Guilherme Reis-de-Oliveira, Victor Corasolla Carregari, Wilson Nadruz, Daniel Martins-de-Souza, Alessandro S. Farias, Licio A. Velloso, José Luiz Proenca-Modena, Marcelo A. Mori, Watson Loh, Deepak L. Bhatt, Derek M. Yellon, Sean M. Davidson, Pedro G. De Oliveira, Pedro M. Moraes-Vieira, Andrei C. Sposito
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2024-10-01
Collection:	Frontiers in Pharmacology
Sujets:	COVID-19 diacerein rhein pre-clinical clinical trial
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1402032/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!